The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (*mdr1a* $^{-/-}$) mice, a model of inflammatory bowel diseases

Katia Nones[1]*, Yvonne E. M. Dommels[1,2], Sheridan Martell[1], Christine Butts[1], Warren C. McNabb[3], Zaneta A. Park[3], Shuotun Zhu[4], Duncan Hedderley[1], Matthew P. G. Barnett[3] and Nicole C. Roy[3]

[1]*Crop and Food Research, Private Bag 11600, Palmerston North 4442, New Zealand*
[2]*Unilever R&D, Unilever Food and Health Research Institute, PO Box 114, Vlaardingen, AC 3130, The Netherlands*
[3]*Food, Metabolism and Microbiology, AgResearch Grasslands, Private Bag 11008, Palmerston North 4442, New Zealand*
[4]*Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand*

Damage of the intestinal epithelial barrier by xenobiotics or reactive oxygen species and a dysregulated immune response are both factors involved in the pathogenesis of inflammatory bowel diseases (IBD). Curcumin and rutin are polyphenolic compounds known to have antioxidant and anti-inflammatory activities, but their mechanism(s) of action are yet to be fully elucidated. Multidrug resistance gene-deficient (*mdr1a* $^{-/-}$) mice spontaneously develop intestinal inflammation, predominantly in the colon, with pathology similar to IBD, so this mouse model is relevant for studying diet–gene interactions and potential effects of foods on remission or development of IBD. The present study tested whether the addition of curcumin or rutin to the diet would alleviate colonic inflammation in *mdr1a* $^{-/-}$ mice. Using whole-genome microarrays, the effect of dietary curcumin on gene expression in colon tissue was also investigated. Twelve mice were randomly assigned to each of three diets (control (AIN-76A), control +0·2 % curcumin or control +0·1 % rutin) and monitored from the age of 7 to 24 weeks. Curcumin, but not rutin, significantly reduced histological signs of colonic inflammation in *mdr1a* $^{-/-}$ mice. Microarray and pathway analyses suggested that the effect of dietary curcumin on colon inflammation could be via an up-regulation of xenobiotic metabolism and a down-regulation of pro-inflammatory pathways, probably mediated by pregnane X receptor (Pxr) and peroxisome proliferator-activated receptor α (Ppara) activation of retinoid X receptor (Rxr). These results indicate the potential of global gene expression and pathway analyses to study and better understand the effect of foods in modulating colonic inflammation.

Colonic inflammation: Gene expression: Curcumin: Rutin: Genome-wide microarrays

Inflammatory bowel diseases (IBD), which include ulcerative colitis and Crohn's disease, are currently thought to be caused by the influence of several genes in combination with complex environmental interactions[1]. IBD is a chronic condition with no known cure, requiring a lifetime of care for patients. A large number of compounds, including some food components, can either alleviate or worsen the condition of IBD patients[2].

The biological processes associated with IBD susceptibility are dysregulated immunoregulation, mucosal barrier integrity and microbial recognition, clearance and/or homeostasis[3]. There is evidence that changes in the epithelial barrier can cause a continuous stimulation of immune cells in IBD patients[4]. The multidrug resistance 1 (*Mdr1*) gene encodes the P-glycoprotein (170 kDa; Abcb1 transporter), which is expressed on epithelial cell surfaces and lymphocytes[5]. *Mdr1a* $^{-/-}$ mice are deficient in these transporters and have an intact immune system, but spontaneously develop colitis triggered by the intestinal bacterial flora[6]. In the absence of

the mdr1 pump (Abcb1 transporters), bacterial products and toxins become sequestered within the epithelial cells, causing damage to the intestinal barrier and subsequently initiating the inflammatory process in *mdr1a* $^{-/-}$ mice[5,6].

Polyphenol compounds are characterised by one or more hydroxyl groups on one or more aromatic rings and are found naturally in fruits, vegetables, grains, roots and tea. *In vitro* and *in vivo* studies have shown that different polyphenol compounds can have anti-allergic, anti-inflammatory, anti-cancer and/or antioxidant activities[7].

Curcumin is a polyphenol and the major constituent of turmeric powder, a spice and colouring agent extracted from the root of *Curcuma longa* and widely used in Asian food. It has been shown that curcumin can inhibit the expression of intercellular adhesion molecule 1 (*Icam1*) and IL-8 (*Il8*) genes, and cytokine-mediated Nfkb activation in intestinal epithelial cells[8]. Salh *et al.*[9] showed that curcumin reduced the activation of Nfkb and the activity of p38 mitogen-activated

---

Abbreviations: CAR, constitutive androstane receptor; HIS, histological injury score; IBD, inflammatory bowel disease; IPA, Ingenuity Pathways Analysis; *mdr1*, multidrug resistance 1; Mapk, mitogen-activated protein kinase; Pxr, pregnane X receptor; Rxr, retinoid X receptor; Saa, serum amyloid A.

* **Corresponding author:** Dr Katia Nones, fax +64 6 3517050, email nonesk@crop.cri.nz

protein kinase (Mapk) in the colon of mice with chemically induced colitis. Sivalingam *et al.* [10] showed that feeding curcumin to rats ameliorated chemically induced oxidative stress in the small intestine. The antioxidant activity of curcumin in liver cells was reported by Sharma *et al.* [11].

Rutin (quercetin-3-rutinoside) is a polyphenolic flavonoid found in buckwheat seeds, citrus fruits and tea [12]. Rutin is rapidly deglycosylated by microbial glycosidases in the large intestine, liberating quercetin in the colon [13]. Rutin's anti-inflammatory effect has been reported to act through: (1) suppression of pro-inflammatory cytokine production in mice with chemically induced colitis [14], and (2) inhibition of Tnf and Nfkb activation in rats with chemically induced colitis [13]. Cruz *et al.* [15] reported that rutin attenuated inflammation in rats with chemically induced colitis, by alleviating oxidative stress in the colon.

Studies have shown that curcumin and rutin have anti-inflammatory and antioxidant properties both *in vitro* and in chemically induced colitis animal models, but their mechanism(s) of action are still not completely understood. The present study was primarily designed to test whether dietary curcumin or rutin can reduce colonic inflammation in *mdr1a* $^{-/-}$ mice, which spontaneously develop intestinal inflammation similar to Crohn's disease [5,16]. Second, we used genome-wide microarrays to evaluate gene expression in colon tissue, to gain more insight into the pathways underlying the effect of dietary curcumin or rutin on colonic inflammation.

Materials and methods

Mice, diet and sample collection

Mdr1a $^{-/-}$ mice were purchased from Taconic Farm, Inc. (Germantown, NY, USA). This trial was approved by AgResearch Grasslands Animal Ethics Committee (Palmerston North, New Zealand), according to the Animal Welfare Act 1999.

Thirty six male *mdr1a* $^{-/-}$ mice, 5–6 weeks old, mean weight 23·6 (SD 0·6) g, were housed individually in cages with pressed wood chips and a plastic tube for environmental enrichment. The room was climate controlled (22–24°C, at approximately 60 % humidity) with a 12 h light–dark cycle. All mice were acclimatised for 1 week before the start of the experiment. Mice were randomly assigned to three treatment groups of twelve animals each. Each treatment group received one of the following diets: (1) control (AIN-76A powdered diet); (2) curcumin (AIN-76A + 0·2 % curcumin; C7727; ≥ 94 % curcuminoid content and ≥ 80 % curcumin; Sigma-Aldrich, Inc., St Louis, MO, USA); (3) rutin (AIN-76A + 0·1 % rutin; R5143; rutin hydrate ≥ 95 %; Sigma-Aldrich Inc.). The composition of the AIN-76A diet was previously described by Dommels *et al.* [16]. Animals received food and water *ad libitum*.

Mice were weighed three times per week throughout the experiment to determine body-weight changes. Food intake was measured during two periods of 4 d at 15 and 18 weeks of age. Food intake was calculated from the amount of food offered during the 4 d minus the remaining and spilt food at the end of the period. On the day before tissue sampling (21 and 24 weeks of age), to minimise the variation between the last meal and sampling, mice were fasted overnight and food was returned the following morning for 2 h before sampling in staggered groups. Six mice from each dietary group were euthanised via

CO_2 asphyxiation and cervical dislocation at 21 weeks of age (sample group 1) and the remaining animals at 24 weeks of age (sample group 2). These time points were selected based on previous results [16] to verify possible time-dependent changes in the colonic inflammation patterns.

Blood was collected from euthanised mice by cardiac puncture. Plasma was separated from erythrocytes by centrifugation (2000 *g*; 10 min; 4°C), frozen in liquid N_2 and stored at − 80°C. The intestine was removed, cut open lengthwise and flushed with 0·9 % NaCl to remove digesta residues. The proximal half of the colon was cut in two pieces, one for histological evaluation and one for gene expression studies. Samples of the colon tissue for gene expression analysis were frozen in liquid N_2 and stored at − 80°C. Samples for histological analysis were stored in formalin solution (10 % neutral buffered) at room temperature.

Histology and serum amyloid A analysis

Formalin-fixed colon samples were embedded in a paraffin block, cut into 5 μm thick sections and stained with haematoxylin and eosin for light microscopic examination. The histological scoring of the inflammation was done with no prior knowledge of the treatments. Scoring of stained sections was based on: (1) inflammatory lesions (mononuclear cell, neutrophil, eosinophil and plasmocyte infiltration, fibrin exudation and lymphangiectasis); (2) tissue destruction (enterocyte loss, ballooning degeneration, oedema and mucosal atrophy); (3) tissue repair (hyperplasia, angiogenesis, granulomas and fibrosis). A score between 0 (no change from normal tissue) and 3 (lesions present in most areas and all layers of the intestinal section including mucosa, muscle and omental fat) was given for each aspect of inflammatory lesions, tissue destruction and tissue repair. The histological injury score (HIS) was calculated as: HIS = ((inflammatory lesions score) × 2) + tissue destruction score + tissue repair score.

The concentration of serum amyloid A (Saa) in the plasma was measured to gain information on systemic inflammation levels and to complement HIS. Plasma (10 μl; diluted 1:5000) was used to assess the Saa concentration using the serum amyloid A (murine) kit (Tridelta Development Limited, Maynooth, County Kildare, Republic of Ireland), as described by the manufacturer.

RNA extraction

Total RNA was extracted from the colon tissues using Trizol (Invitrogen, Carlsbad, CA, USA) as described by the manufacturer, with a subsequent purification step using RNeasy columns (Qiagen, San Diego, CA, USA). RNA was quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and RNA quality was examined using an RNA 6000 LabChip Kit and a 2100 Bioanalyser (Agilent Technologies, Palo Alto, CA, USA). Only total RNA with a 260:280 nm ratio ≥2·0, a 28S:18S peak ratio ≥0·8 and an RNA integrity number ≥6·5 was used for microarray and quantitative real-time PCR analysis.

Microarray hybridisations

As only curcumin significantly reduced colonic HIS, comparison of the gene expression levels in colon was carried out

using total RNA from colon tissue of four $mdr1a^{-/-}$ mice from the control group (high HIS) and four $mdr1a^{-/-}$ mice from the curcumin group (low HIS). A reference design with eight arrays was used for this comparison, where each individual RNA sample was hybridised in the array with the reference RNA, in a total of four biological replicates per treatment. Reference RNA was produced by pooling equal amounts of total RNA extracted from the small intestine, colon, kidney and liver of normal healthy Swiss mice plus RNA extracts from Swiss mouse fetuses.

cDNA and cRNA were synthesised using the Low RNA Input Linear Amplification Kit (Agilent Technologies), following the manufacturer's instructions. Reverse transcription used 500 ng of total RNA and oligo-dT primers. cRNA was synthesised and labelled with cyanine3 (samples) and cyanine5 (reference) dye (Perkin-Elmer/NEN Life Science, Boston, MA, USA) and the dye incorporation evaluated using a Nanodrop ND-1000 spectrophotometer. Samples ranged from 10 to 22 pmol dye/μg RNA. Labelled cRNA were hybridised using an *In Situ* Hybridization Plus Kit (Agilent Technologies), following the manufacturer's protocols, using 750 ng of experimental and reference cRNA onto 44K mouse oligonucleotide arrays (Agilent Technologies). After hybridisation, slides were washed in solutions I, II and III (Agilent Technologies) and air-dried. Slides were scanned using a GenePix Professional 4200A scanner (Molecular Devices, Sunnyvale, CA, USA) with a photomultiplier tube voltage of 580 V. All slides were individually checked and manually flagged for abnormalities. The microarray data are available as accession GSE10684 in the Gene Expression Omnibus repository at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo/info/linking.html).

Quantitative real-time polymerase chain reaction

Six genes were selected from genes differentially expressed in the microarray analysis for quantitative real-time PCR verification of the microarray results. cDNA was synthesised from the same total RNA samples used for the microarray analysis, using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany). Reverse transcription used 1·0 μg of total RNA and oligo-dT primers (50 pmol) according to the manufacturer's instructions. The PCR conditions were 95°C for 5 min, then thirty-five cycles at 95°C for 15 s, 63°C for 10 s and 72°C for 15 s. Melting curves were assessed by increasing the temperature by 1°C/s from 65°C to 95°C.

Primers for the selected genes were as follows: cytochrome P450, family 2, subfamily C, polypeptide 40 (*Cyp2c40*, NM_010004.1 – forward primer: ATAGGATGTGCTCCCTGC; reverse primer: AAGGTCTCTGTCCCACCA); carboxylesterase 2 (*Ces2*, NM_145603.1 – forward primer: CACGGAACCAACTACATAAC; reverse primer: AGACATAGGGAAGGAAGACA); sulfotransferase 1A member 1 (*Sult1a1*, NM_133670.1 – forward primer: GGATGTGGTTGTCTCCTATT; reverse primer: GGATGGTTGTGTAGTTAGCC); interferon γ (*Ifng*, NM_008337.1 – forward primer: AAGTGGCATAGATGTGGAA; reverse primer: GCTTATGTTGTTGCTGATG); CD44 antigen (*Cd44*, AK045226.1 – forward primer: AACACACCAAGAAGACATCG; reverse primer: CCTGATCTCCAGTAGGCTGT) and neutrophil cytosolic

factor 4 (*Ncf4*). Primers (except *Ncf4* [16]) were designed using Primer 3.0 [17], with available public sequences. PCR conditions for all primers were optimised and amplicons were sequenced to confirm identity. Specificities of all PCR reactions were verified in melting curves analyses and in agarose gel. Data were normalised against the geometrical mean of two reference genes (hypoxanthine guanine phosphoribosyl transferase 1 (*Hprt*) and calnexin (*Canx*) [16]).

Threshold cycle (Ct) values were obtained in duplicate in independent runs for each sample on a Rotor Gene 3000 (Corbett Research, Sydney, NSW, Australia) using Light-Cycler 480 SYBR Green I Master (Roche Diagnostics), according to the manufacturer's protocol for 20 μl reactions. PCR efficiencies for all runs and primer sets were calculated for each individual sample using the LinRegPCR program [18]. As the PCR efficiencies were similar in all reactions (average 2·03 (SD 0·04)), the $2^{-\Delta\Delta CT}$ method was used for relative quantification.

Pathway analyses

Data from the microarray experiment, comparing colonic gene expression from $mdr1a^{-/-}$ mice fed control and curcumin diets, were used in the pathway analyses to gain more insight into pathways underlying the beneficial effect of curcumin on colonic inflammation. Pathways were generated using the Ingenuity Pathways Analysis (IPA) program (Ingenuity® Systems, Redwood City, CA, USA; www.ingenuity.com) that enables the identification of biologically relevant networks.

Data from microarray analysis containing probe identifiers (gene accession number), the corresponding change in expression value (fold change) and false discovery rate (shown by *q* values) were uploaded into the IPA program. Only probes from the microarray dataset that met the cut-off criteria of a 1·5-fold change in expression (up- or down-regulated) and a *q* value of less than 0·05 were considered for the pathway analysis. Each probe identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base. Biological function and relevant metabolic and signalling pathways were assigned to each gene and the most significant pathways ranked according to the significance of the data.

Statistical analysis

Statistical analysis of body weight, food intake, histology and Saa data was performed using ANOVA, followed by the least significant difference *post hoc* test (GenStat for Windows version 9; VSN International Ltd, Hemel Hempstead, Herts, UK). For all ANOVA analyses, the data were log-transformed before analysis if necessary, to ensure that the variances for all groups were similar. Gene expression analysis was only performed if significant changes in HIS ($P < 0.05$) were observed in the colon tissue.

Microarray data were analysed using the Limma package in Bioconductor [19]. Image analyses of the extracted foreground and background fluorescence intensity measurements were evaluated to select the best background correction for the experiment, but no background correction was necessary due to homogeneous hybridisation. Data were normalised using a local linear regression analysis (LOESS) to remove the effect of systematic variation in the microarrays.

Box plots, density plots and spatial images of the raw and normalised data were examined in order to check the quality of the microarray data, and that no unusual results for any slide were observed. Data were log-transformed before analysis and the mean difference between treatments calculated on this scale, resulting in a log ratio for each probe. MA plots of the microarray data were drawn in order to check that there was no dependence of the log ratio on the intensity for any slide. The significance of the log ratio for each probe was determined by calculating one modified *t* statistic per probe using an empirical Bayesian approach[20].

The probability values were then corrected for multiple testing using the Benjamini–Hochberg correction[21], and a false discovery rate calculated. Probes that had a false discovery rate of less than 5 % ($q < 0.05$) were considered to be differentially expressed between the groups fed the control and curcumin diets. Log ratios have been converted to fold change when presenting results, as fold change is a more meaningful variable in biological terms.

Pathways were considered significantly affected by curcumin when the probability value calculated using the right-tailed Fisher's exact test was smaller than 0·01 and at least 10 % of the genes from a particular pathway were differentially expressed in the microarray experiment.

One-way ANOVA (GenStat for Windows version 9; VSN International Ltd) was used for statistical analyses of the quantitative real-time PCR data, and gene expression was considered different when the probability was inferior to 0·05.

Results

Weight gain and food intake

There were no differences ($P > 0.05$) in body weight between the mice fed the different diets at 21 and 24 weeks of age (Table 1). The average body weight of the mice is presented in Fig. 1, showing the average growth curve during the experiment. Food intake was similar ($P > 0.05$) between mice fed all three diets at 15 and 18 weeks of age (Table 1). Some animals died during the experiment; three mice from the group fed the control diet, three mice from the group fed the rutin diet and two mice from the group fed the curcumin diet. These mice showed signs of colonic inflammation but were not included in the analyses because they died before the scheduled sampling times.

Histology and serum amyloid A

There were no differences on HIS in the colon ($P > 0.05$) between the two sampling groups (21 and 24 weeks of age) within each dietary treatment (data not shown). For this reason, animals were grouped by diet for further analyses. The average HIS was significantly reduced ($P = 0.02$) in the colon from mice fed curcumin compared with those fed the control or rutin diets. Table 2 shows that HIS was mainly characterised by cell infiltration (monocytes and neutrophils) and by tissue destruction (enterocyte loss and oedema). Characteristic signs of inflammation were prominent thickening of the mucosal layer, disappearance of crypts, epithelial cell hyperplasia and goblet cell loss in the remaining crypts. Curcumin reduced cell damage and the number of inflammatory cells present in the lamina propria (Fig. 2).

The concentration of Saa in the plasma normally increases in response to tissue injury and inflammation. Plasma Saa concentration has been suggested as an inflammatory marker to monitor chronic diseases such as arthritis[22] and asthma[23]. In the present study, the average plasma Saa concentration from mice fed the control diet was 0·424 μg/ml, the curcumin diet 0·135 μg/ml and the rutin diet 0·337 μg/ml. Plasma Saa concentration showed the same trend as the HIS, where curcumin reduced signs of colonic inflammation in *mdr1a* $^{-/-}$ mice, but was not significantly different ($P = 0.27$) from the other diets.

Microarray analysis

From the 44 000 oligonucleotide probes in the microarray, 2308 probes were differentially expressed ($q < 0.05$) in the colon of mice fed the curcumin-enriched diet compared with those fed the control diet. Of these differentially expressed probes, 1319 (57 %) were down-regulated (−1·19- to −9·09-fold) and 989 (43 %) were up-regulated (1·19- to 13·37-fold) in the colon of *mdr1a* $^{-/-}$ mice fed the curcumin diet compared with those fed the control diet.

Quantitative real-time polymerase chain reaction

To confirm the findings of the microarray analyses, quantitative real-time PCR analyses were carried out on six selected genes from the set of differentially expressed genes. Detoxification genes *Ces2*, *Cyp2c40* and *Sult1a1* were up-regulated ($P < 0.05$) in the colon of the *mdr1a* $^{-/-}$ mice fed

Table 1. Body weight (g) and food intake (g) during the experiment of multidrug resistance gene-deficient (*mdr1a* $^{-/-}$) mice fed control, curcumin and rutin diets

(Mean values and standard deviations)

| | Body weight | | | | | | Food intake* | | | |
| | 6 weeks | | 21 weeks | | 24 weeks | | Week 15 | | Week 18 | |
Diet group	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Control (*n* 9)	23·9	0·5	27·7	0·1	29·2	0·6	4·7	0·1	4·3	0·3
Curcumin (*n* 10)	23·6	0·6	28·4	0·2	29·5	0·1	4·8	0·1	4·8	0·1
Rutin (*n* 9)	23·3	0·6	26·2	0·2	30·4	0·1	4·5	0·1	4·7	0·1

* Food intake was measured during two periods of 4 d at 15 and 18 weeks of age.

Fig. 1. Body weight of multidrug resistance gene-deficient ($mdr1a^{-/-}$) mice fed control (–◆–), rutin (–✕–) and curcumin (–▲–) diets as a function of age. Values are means for each time point. No difference was observed in the body weight of mice fed the different diets.

the curcumin diet compared with those fed the control diet. Genes *Ifng*, *Cd44* and *Ncf4*, which are involved in the immune response process, were down-regulated in the colon of the mice fed the curcumin diet ($P < 0.05$) compared with the colon of the mice fed the control diet. Similar expression patterns were observed for the six genes tested by quantitative real-time PCR and microarray (Fig. 3), suggesting that the results from the microarrays could confidently be used to identify pathways altered by curcumin.

Pathway analyses

The 2308 oligonucleotides probes differentially expressed in the microarray experiment ($q < 0.05$) corresponded to 830 annotated genes (Ingenuity Pathways Knowledge Base) that met the cut-off (1·5-fold change and $q < 0.05$). From those, 757 genes were associated with a biological function or disease in the IPA program and used for pathway analysis.

The most significant biological functions affected by dietary curcumin were grouped into three IPA categories: (1) diseases and disorders; (2) molecular and cellular functions; (3) physiological system development and function. The top five functions in these categories and the number of genes differentially expressed in the microarray experiment that were grouped in those functions are shown in Table 3.

From the 757 genes associated with a biological function in IPA, 222 genes (29 %) were identified as immune response

Table 2. Histology injury score (HIS) and principal histological aspects (monocytes, neutrophils, oedema and enterocyte loss) identified in the colon of multidrug resistance gene-deficient ($mdr1a^{-/-}$) mice

(Mean values)

Diet	HIS*	Monocytes	Neutrophils	Oedema/ enterocyte loss
Control (n 9)	9·31	4·50	3·00	1·78
Curcumin (n 10)	4·70†	2·80†	1·20†	0·45†
Rutin (n 9)	9·86	4·78	3·17	1·89
P	0·02	0·01	0·04	0·005
LSD (25 df)	4·08	1·42	1·75	0·94

LSD, least significant difference.
* A small part of the HIS includes other histological aspects (data not shown).
† Mean value is significantly different from those of the control and rutin groups ($P < 0.05$).

genes and 145 genes (19 %) were associated with tissue development (Table 3), suggesting an effect of curcumin in immune response and tissue repair. These results support the colonic HIS results, in which mice fed dietary curcumin had colons with reduced cell damage and fewer inflammatory cells in the lamina propria.

The following pathways involved in immune and inflammatory response were affected by dietary curcumin: (1) complement and coagulation cascades; (2) Il10 signalling; (3) lipopolysaccharide/Il1-mediated inhibition of retinoid X receptor (Rxr) function; (4) leucocyte extravasation signalling; (5) Il6 signalling; (6) p38 Mapk signalling; (7) natural killer-cell signalling; (8) Nfkb signalling pathway; (9) positive acute-phase response proteins ($P < 0.001$ and more than 10 % of the genes belonging to those pathways were differentially expressed). Genes involved in immune and inflammatory responses were generally down-regulated in the colon of the mice fed curcumin compared with those fed the control diet (Table 4), suggesting an anti-inflammatory effect.

An effect of dietary curcumin was also observed in the following pathways: (1) xenobiotic metabolism signalling; (2) metabolism of xenobiotic by cytochrome P450; (3) cytochrome P450 panel – substrate is a xenobiotic; (4) xenobiotic metabolism; (5) oxidative stress (Table 5). Genes involved in xenobiotic metabolism were up-regulated. Genes involved in the oxidative stress response were generally down-regulated, suggesting an antioxidative effect of the curcumin diet in the colon of the $mdr1a^{-/-}$ mice.

Pathways related to Rxr activity were also affected by curcumin: lipopolysaccharide/Il1-mediated inhibition of Rxr function, pregnane X receptor (Pxr)/Rxr activation, constitutive androstane receptor (CAR)/Rxr activation, vitamin D receptor/Rxr activation and Pparα/Rxrα activation. Genes from those pathways were differentially expressed in the colon of curcumin-fed mice compared with the control mice (Table 6), suggesting that curcumin could affect expression of several genes through those pathways as Rxr regulates the expression of several genes involved in xenobiotic metabolism and immune response. The effect of curcumin on colonic inflammation could indeed be through those key receptors.

Two pathways involved in fibrosis development (hepatic fibrosis and hepatic stellate cell activation) were significantly affected by dietary curcumin. Genes from those pathways were down-regulated (Table 7), suggesting that curcumin could inhibit the fibrogenesis process in colon tissue.

Pathways involved in amino acid and fatty acid metabolism were also affected by dietary curcumin; genes involved in those pathways were generally up-regulated (Table 8).

Discussion

In the present study, $mdr1a^{-/-}$ mice fed a diet containing curcumin had a lower colonic HIS than those fed the control diet. This supports previous studies, which have shown curcumin as a potent anti-inflammatory agent[9,10]. To our knowledge this is the first study using genome-wide gene expression to investigate the effect of curcumin on colonic inflammation in an animal model that spontaneously develops colitis. Microarrays can be used to identify genes and/or pathways that could be relevant to IBD, allowing an unbiased overview of the

Fig. 2. Multidrug resistance gene-deficient (*mdr1a* $^{-/-}$) colon sections stained with haematoxylin and eosin. Original magnification 100 ×. Colon segments of *mdr1a* $^{-/-}$ mice fed: (A) the control diet, showing signs of inflammation, i.e. a high number of inflammatory cells (←), crypt abscesses and loss of goblet cells in the lamina propria (K); (B) the rutin diet, showing signs of inflammation, i.e. a high number of inflammatory cells (←), crypt abscesses and loss of goblet cells in the lamina propria (K); (C) the curcumin diet, showing reduction of inflammation compared with animals fed the control and rutin diets, i.e. a lower number of inflammatory cells (←) and presence of crypt and goblet cells (◄) in the lamina propria (K).

disease's pathogenesis, and this approach may uncover new targets for further studies and future IBD therapy[24].

Several pathways linked to immune and inflammatory responses were significantly affected by dietary curcumin (Table 4). The expression of the pro-inflammatory cytokines, Il1b, Tnf and interferon γ, previously associated with IBD, was down-regulated in the colon of mice fed dietary curcumin. The expression of several chemokines involved in the leucocyte extravasation signalling pathway was also down-regulated in the colon of those animals. Their down-regulation supports the observed reduction of neutrophil and monocyte infiltration in the lamina propria of the colon from mice fed dietary curcumin (Table 2).

Reyes-Gordillo *et al.*[25] suggest that curcumin prevents chemically induced acute liver damage by at least two mechanisms: (1) acting as an antioxidant, and (2) inhibiting Nfkb activation and thus reducing the production of pro-inflammatory cytokines. In the present study, genes involved in the oxidative stress and the Nfkb signalling pathways were mostly down-regulated by the curcumin-supplemented diet, and this suggests that curcumin may affect those pathways in the colon.

Genes involved in the p38 Mapk signalling pathway (*Fas, Il1b, Il1r1, Il1r2, Il1rn, Pla2g2d, Stat1, Tgfbr1, Tgfbr2, Tnf* and *Tnfrsf1b*) were also down-regulated in the colon of mice

fed dietary curcumin compared with the controls. This pathway was previously reported to be inhibited by curcumin in the colon of rats with chemically induced colitis[26]. Receptors such as Tnf, Il1 receptor, toll-like receptor 2, monocyte differentiation antigen CD14, which regulate the activation of Nfkb and Mapk pathways[3], were down-regulated in the colon of mice fed dietary curcumin. This suggests that the effects of curcumin in the inflammatory responses in the colon of *mdr1a* $^{-/-}$ mice may be through Nfkb and Mapk pathways.

Genes involved in pathways of the xenobiotic metabolism were significantly up-regulated in the colon of mice fed dietary curcumin. Detoxification genes, including phase 1 and 2 enzymes such as cytochrome P450 (*Cyp* enzymes), carboxylesterase (*Ces2*), glutathione *S* transferases (*Gsta3, Gstm1, Gstm2, Gstm3, Gstm5*), UDP-glucuronosyltransferase (*Ugt2b10*) and sulfotransferases (*Sult1a1, Sult1b1, Sult1d1*), were up-regulated in colon of mice fed curcumin (low-HIS) compared with those fed the control diet (high-HIS). These results support those observed by Langmann *et al.*[4], who showed a down-regulation of detoxification genes in inflamed colon biopsies of IBD patients compared with control patients and


Fig. 3. Change in gene expression of fold change (*n* 4) in the colon of multidrug resistance gene-deficient (*mdr1a* $^{-/-}$) mice fed the curcumin diet compared with mice fed the control diet for selected genes tested by microarray (■) and quantitative real-time PCR (□). Values are means, with standard deviations represented by vertical bars. Gene expression was significantly different for the six genes in both microarray ($q < 0.05$) and quantitative real-time PCR ($P < 0.05$). Quantitative real-time PCR data were normalised for the geometric mean of reference genes. *Cd44*, CD44 antigen; *Ces2*, carboxylesterase 2; *Cyp2c40*, cytochrome P450 family 2 subfamily C polypeptide 40; *Ifng*, interferon γ; *Ncf4*, neutrophil cytosolic factor 4; *Sult1a1*, sulfotransferase family 1A phenol-preferring member 1.

Table 3. Significant functions ($P < 0.0001$) affected by dietary curcumin as assessed by Ingenuity Pathways Analysis (IPA)*

Function	Number of genes/function
Diseases and disorders	
Inflammatory disease	122
Immunological disease	120
Connective tissue disorder	90
Skeletal and muscular disorder	63
Cancer	279
Molecular and cellular function	
Cellular movement	191
Cell-to-cell signalling and interaction	195
Cellular growth and proliferation	261
Cellular signalling	290
Molecular transport	138
Physiological system development and function	
Immune response	222
Haematological system development and function	207
Immune and lymphatic system development	177
Tissue morphology	138
Tissue development	145

* Functions were grouped into three IPA categories; the Table shows the number of genes differentially expressed in the microarray experiment grouped within a given function.

Table 4. Immune and inflammatory response genes differentially expressed in the colon of multidrug resistance gene-deficient (mdr1a$^{-/-}$) mice fed the curcumin diet compared with the colon of mice fed the control diet*

Gene symbol	Description	Accession number	Mean fold change	q value†
Arg2	Arginase, type II	NM_009705	−1·56	0·04
C1qa	Complement component 1, q subcomponent, A chain	NM_007572	−2·17	0·002
C1qb	Complement component 1, q subcomponent, B chain	NM_009777	−1·52	0·009
C1qc	Complement component 1, q subcomponent, C chain	NM_007574	−2·38	<0·001
C1r	Complement component 1, r subcomponent	NM_023143	−2·94	<0·001
C1s	Complement component 1, s subcomponent	NM_144938	−2·86	<0·001
C2	Complement component 2	NM_013484	−1·96	0·001
C3	Complement component 3	NM_009778	−1·85	0·03
C4b	Complement component 4B (Childo blood group)	NM_009780	−2·27	0·001
Ccr1	Chemokine (C-C motif) receptor 1	NM_009912	−2·08	0·008
Cd14	CD14 molecule	NM_009841	−1·96	0·03
Cd44	CD44 molecule (Indian blood group)	AK045226	−2·5	<0·001
Cdh5	Cadherin 5, type 2, VE-cadherin (vascular epithelium)	NM_009868	−1·79	0·03
Cebpb	CCAAT/enhancer binding protein (C/EBP), β	NM_009883	−2·13	0·03
Cfb	Complement factor B	NM_008198	−1·67	0·02
Cfh	Complement factor H	NM_009888	−2·78	0·001
Cldn3	Claudin 3	NM_009902	1·66	0·003
Col1a1	Collagen, type I, α 1	NM_007742	−3·23	0·001
Cp	Ceruloplasmin (ferroxidase)	NM_007752	−2·78	<0·001
Cxcl12	Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)	NM_021704	−2·27	0·001
Cxcl13	Chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)	NM_018866	−2·17	0·02
Cxcl14	Chemokine (C-X-C motif) ligand 14	NM_019568	−2·38	<0·001
Cxcl16	Chemokine (C-X-C motif) ligand 16	NM_023158	−1·96	0·001
Cyba	Cytochrome b-245, α polypeptide	NM_007806	−2·04	<0·001
Cybb	Cytochrome b-245, β polypeptide (chronic granulomatous disease)	NM_007807	−3·70	<0·001
Ddit3	DNA-damage-inducible transcript 3	NM_007837	1·77	0·01
F10	Coagulation factor X	NM_007972	−3·13	<0·001
F2r	Coagulation factor II (thrombin) receptor	NM_010169	−1·85	<0·001
Fas	Fas (TNF receptor superfamily, member 6)	NM_007987	−1·64	0·001
Fcgr2a	Fc fragment of IgG, low affinity IIa, receptor (CD32)	NM_010188	−3·03	<0·001
Fcgr2b	Fc fragment of IgG, low affinity IIb, receptor (CD32)	NM_010187	−3·23	<0·001
Gnai1	Guanine nucleotide binding protein (G protein), α inhibiting activity polypeptide 1	XM_355574	1·63	0·02
Icam1	Intercellular adhesion molecule 1 (CD54)	BC008626	−3·13	<0·001
Il18	IL-18 (interferon-γ-inducing factor)	NM_008360	2·47	<0·001
Il1b	IL-1, β	NM_008361	−5·00	0·003
Il1r1	IL-1 receptor, type I	NM_008362	−1·82	<0·001
Il1r2	IL-1 receptor, type II	NM_010555	−2·22	0·005
Il1rn	IL-1 receptor antagonist	NM_031167	−1·75	0·04
Ifng	Interferon, γ	NM_008337	−2·78	0·008
Itgam	Integrin, α M (complement component 3 receptor 3 subunit)	AK040921	−1·85	0·03
Itgb2	Integrin, β 2 (complement component 3 receptor 3 and 4 subunit)	NM_008404	−1·70	0·004
Lbp	Lipopolysaccharide binding protein	NM_008489	−1·67	0·002
Lck	Lymphocyte-specific protein tyrosine kinase	NM_010693	−1·64	0·005
Map2k1	Mitogen-activated protein kinase kinase 1	NM_008927	1·91	0·001
Map3k8	Mitogen-activated protein kinase kinase kinase 8	NM_007746	−1·52	0·004
Masp1	Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor)	AK031598	−1·85	<0·001
Mmp13	Matrix metallopeptidase 13 (collagenase 3)	NM_008607	−2·50	<0·001
Mmp14	Matrix metallopeptidase 14 (membrane-inserted)	NM_008608	−2·78	<0·001
Mmp3	Matrix metallopeptidase 3 (stromelysin 1, progelatinase)	NM_010809	−5·26	0·009
Mmp7	Matrix metallopeptidase 7 (matrilysin, uterine)	NM_010810	−5·56	<0·001
Ncf1c	Neutrophil cytosolic factor 1C pseudogene	NM_010876	−1·67	0·004
Ncf2	Neutrophil cytosolic factor 2 (65 kDa, chronic granulomatous disease, autosomal 2)	NM_010877	−2·22	<0·001
Ncf4	Neutrophil cytosolic factor 4, 40 kDa	NM_008677	−3·13	<0·001
Nfkbia	Nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor, α	NM_010907	−2·08	0·004
Nfkbie	Nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor, ε	NM_008690	−1·70	0·04
Pik3cd	Phosphoinositide-3-kinase, catalytic, δ polypeptide	NM_008840	−2·17	0·001
Pik3r3	Phosphoinositide-3-kinase, regulatory subunit 3	NM_181585	1·54	0·005
Pla2g10	Phospholipase A2, group X	NM_011987	1·68	<0·001
Pla2g2d	Phospholipase A2, group IID	NM_011109	−1·72	0·04
Plat	Plasminogen activator, tissue	NM_008872	−1·54	0·03
Plg	Plasminogen	NM_008877	−1·52	0·03
Prkcd	Protein kinase C, δ	NM_011103	1·62	0·005
Prkce	Protein kinase C, ε	AK017901	1·54	0·005
Prkcz	Protein kinase C, ζ	BC072590	2·00	<0·001
Selplg	Selectin P ligand	NM_009151	−1·79	0·015

Table 4. *Continued*

Gene symbol	Description	Accession number	Mean fold change	q value†
Serpina3	Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 3	NM_009252	−2·56	0·004
Serping1	Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)	NM_009776	−2·04	0·02
Socs3	Suppressor of cytokine signalling 3	NM_007707	−3·23	0·01
Spn	Sialophorin (leukosialin, CD43)	AK077764	−2·38	0·003
Stat1	Signal transducer and activator of transcription 1	NM_009283	−2·44	0·002
Tgfbr1	Transforming growth factor, β receptor I (activin A receptor type II-like kinase, 53 kDa)	NM_009370	−1·54	0·04
Tgfbr2	Transforming growth factor, β receptor II (70/80 kDa)	NM_009371	−1·85	<0·001
Thy1	Thy-1 cell surface antigen	NM_009382	−2·27	0·004
Timp1	TIMP metallopeptidase inhibitor 1	NM_011593	−1·96	0·001
Tlr2	Toll-like receptor 2	NM_011905	−2·27	0·002
Tnf	Tumour necrosis factor (TNF superfamily, member 2)	NM_013693	−1·70	0·01
Tnfrsf1b	Tumour necrosis factor receptor superfamily, member 1B	NM_011610	−1·79	0·01
Tnfsf13b	Tumour necrosis factor (ligand) superfamily, member 13b	NM_033622	−1·85	0·02
Vcam1	Vascular cell adhesion molecule 1	NM_011693	−4·17	<0·001
Vil2	Villin 2 (ezrin)	NM_009510	1·55	0·02
Wipf1	WAS/WASL interacting protein family, member 1	NM_153138	−1·75	0·002

* Genes were grouped into one or more of the following Ingenuity Pathways Analysis pathways: complement and coagulation cascades, Il10 signalling, lipopolysaccharide/Il1-mediated inhibition of retinoid X receptor function, leucocyte extravasation signalling, Il6 signalling, p38 mitogen-activated protein kinase signalling, natural killer-cell signalling, Nfkb signalling and positive acute-phase response proteins.
† Only genes with a false discovery rate <5 % ($q < 0·05$) and fold change >1·5 were considered for pathway analysis.

Table 5. Xenobiotic metabolism and oxidative stress genes differentially expressed in the colon of multidrug resistance gene-deficient ($mdr1a^{-/-}$) mice fed the curcumin diet compared with the colon of mice fed the control diet*

Gene symbol	Description	Accession number	Mean fold change	q value†
Adh1	Alcohol dehydrogenase 1C (class I), γ polypeptide	NM_007409	1·98	0·003
Akr1c4	Aldo-keto reductase family 1, member C4	NM_001013785	2·70	<0·001
Aldh2	Aldehyde dehydrogenase 2 family (mitochondrial)	NM_009656	2·02	0·006
Aldh3b1	Aldehyde dehydrogenase 3 family, member B1	NM_026316	−1·79	<0·001
Ccl5	Chemokine (C-C motif) ligand 5	BC033508	−3·45	<0·001
Ces2	Carboxylesterase 2	NM_145603	4·03	<0·001
Cyp2c18	Cytochrome P450, family 2, subfamily C, polypeptide 18	NM_028089	3·52	0·002
Cyp2c19	Cytochrome P450, family 2, subfamily C, polypeptide 19	NM_010003	2·45	0·001
Cyp2c40	Cytochrome P450, family 2, subfamily C, polypeptide 40	NM_010004	5·07	<0·001
Cyp2c9	Cytochrome P450, family 2, subfamily C, polypeptide 9	NM_007815	2·54	0·002
Cyp2d10	Cytochrome P450, family 2, subfamily D, polypeptide 10	NM_010005	2·48	<0·001
Cyp2d13	Cytochrome P450, family 2, subfamily D, polypeptide 13	NM_133695	1·86	<0·001
Cyp2d26	Cytochrome P450, family 2, subfamily D, polypeptide 26	NM_029562	1·73	<0·001
Cyp2d9	Cytochrome P450, family 2, subfamily D, polypeptide 9	NM_010006	2·98	<0·001
Cyp2f1	Cytochrome P450, family 2, subfamily F, polypeptide 1	NM_007817	1·91	0·009
Cyp2s1	Cytochrome P450, family 2, subfamily S, polypeptide 1	NM_028775	2·80	<0·001
Cyp3a7	Cytochrome P450, family 3, subfamily A, polypeptide 7	NM_007819	3·43	<0·001
Ephx2	Epoxide hydrolase 2, cytoplasmic	NM_007940	2·37	<0·001
Gpx2	Glutathione peroxidase 2 (gastrointestinal)	NM_030677	−1·67	0·048
Gsta3	Glutathione S-transferase A3	NM_010356	1·58	0·04
Gstm1	Glutathione S-transferase M1	NM_008183	1·62	0·003
Gstm3	Glutathione S-transferase, mu 3	NM_010359	1·83	0·003
Gstm5	Glutathione S-transferase M5	NM_010358	2·02	0·001
Icam1	Intercellular adhesion molecule 1 (CD54)	BC008626	−3·13	<0·001
Mgst3	Microsomal glutathione S-transferase 3	AK008211	2·11	<0·001
Mpo	Myeloperoxidase	NM_010824	−1·75	0·044
Prdx6	Peroxiredoxin 6	NM_007453	2·12	0·02
S100a9	S100 Ca-binding protein A9	NM_009114	−5·88	0·006
Sult1a1	Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1	NM_133670	4·47	<0·001
Sult1b1	Sulfotransferase family, cytosolic, 1B, member 1	NM_019878	1·87	0·009
Sult1d1	Sulfotransferase family 1D, member 1	NM_016771	2·21	0·001
Tnf	Tumour necrosis factor (TNF superfamily, member 2)	NM_013693	−1·70	0·01
Ugt2b10	UDP glucuronosyltransferase 2 family, polypeptide B10	NM_153598	1·68	0·01
Vcam1	Vascular cell adhesion molecule 1	NM_011693	−4·17	<0·001

* Genes were grouped into one or more of the following Ingenuity Pathways Analysis pathways: xenobiotic metabolism signalling, metabolism of xenobiotic by cytochrome P450, cytochrome P450 panel – substrate is a xenobiotic, xenobiotic metabolism and oxidative stress.
† Only genes with a false discovery rate <5 % ($q < 0·05$) and fold change >1·5 were considered for pathway analysis.

Table 6. Genes involved in retinoid X receptor (Rxr) activation pathways differentially expressed in the colon of multidrug resistance gene-deficient ($mdr1a^{-/-}$) mice fed the curcumin diet compared with the colon of mice fed the control diet*

Gene symbol	Description	Accession number	Mean fold change	q value†
Abcb11	ATP-binding cassette, sub-family B (MDR/TAP), member 11	NM_021022	−1·82	0·03
Abcc4	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	AK032802	−1·82	0·03
Acadm	Acyl-coenzyme A dehydrogenase, C-4 to C-12 straight chain	NM_007382	1·59	0·003
Acox1	Acyl-coenzyme A oxidase 1, palmitoyl	NM_015729	2·12	0·001
Aldh1a1	Aldehyde dehydrogenase 1 family, member A1	NM_013467	1·58	0·04
Aldh1a7	Aldehyde dehydrogenase family 1, subfamily A7	NM_011921	1·79	0·02
Apoe	Apolipoprotein E	NM_009696	−1·79	0·001
C2	Complement component 2	NM_013484	−1·96	0·001
C3	Complement component 3	NM_009778	−1·85	0·03
Ces2	Carboxylesterase 2	NM_145603	4·03	<0·001
Cyp2c18	Cytochrome P450, family 2, subfamily C, polypeptide 18	NM_028089	3·52	0·002
Cyp2c19	Cytochrome P450, family 2, subfamily C, polypeptide 19	NM_010003	2·45	0·001
Cyp2c9	Cytochrome P450, family 2, subfamily C, polypeptide 9	NM_007815	2·54	0·002
Cyp3a7	Cytochrome P450, family 3, subfamily A, polypeptide 7	NM_007819	3·43	<0·001
Gsta3	Glutathione S-transferase A3	NM_010356	1·58	0·04
Hadh	Hydroxyacyl-coenzyme A dehydrogenase	AK199677	1·70	0·001
Hadhb	Hydroxyacyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme A hydratase, β subunit	NM_145558	1·58	0·001
Hmgcs1	3-Hydroxy-3-methylglutaryl-coenzyme A synthase 1	NM_145942	1·76	0·04
Il18	IL-18 (interferon-γ-inducing factor)	NM_008360	2·47	<0·001
Il1b	IL-1, β	NM_008361	−5·00	0·003
Il1r1	IL-1 receptor, type I	NM_008362	−1·82	<0·001
Il1r2	IL-1 receptor, type II	NM_010555	−2·22	0·005
Il1rn	IL-1 receptor antagonist	NM_031167	−1·75	0·04
Lbp	Lipopolysaccharide binding protein	NM_008489	−1·67	0·002
Map2k1	Mitogen-activated protein kinase kinase 1	NM_008927	1·91	0·001
Nfkbia	Nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor, α	NM_010907	−2·08	0·004
Nfkbie	Nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor, ε	NM_008690	−1·70	0·04
Nr5a2	Nuclear receptor subfamily 5, group A, member 2	NM_030676	1·92	0·03
Pck1	Phosphoenolpyruvate carboxykinase 1 (soluble)	NM_011044	2·16	0·02
Pdgfa	Platelet-derived growth factor α polypeptide	NM_008808	1·64	0·001
Pdgfc	Platelet-derived growth factor C	NM_019971	−1·54	0·011
Ppara	PPARα	NM_011144	1·74	<0·001
Pargc1a	PPARγ, coactivator 1 α	NM_008904	2·25	0·002
Sult1a1	Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1	NM_133670	4·47	<0·001
Sult1b1	Sulfotransferase family, cytosolic, 1B, member 1	NM_019878	1·87	0·009
Sult1d1	Sulfotransferase family 1D, member 1	NM_016771	2·21	0·001
Tnf	TNF superfamily, member 2	NM_013693	−1·70	0·01
Tnfrsf1b	Tumour necrosis factor receptor superfamily, member 1B	NM_011610	−1·79	0·01

* Genes were grouped into one or more of the following Ingenuity Pathways Analysis pathways: lipopolysaccharide/Il1-mediated inhibition of Rxr function, pregnane X receptor/Rxr activation, constitutive androstane receptor/Rxr activation, vitamin D receptor/Rxr activation and Ppara/Rxrα activation.

† Only genes with a false discovery rate <5 % (q < 0·05) and fold change >1·5 were considered for pathway analysis.

our previous results[16] where we observed a down-regulation of detoxification genes in the inflamed colonic epithelial cells of $mdr1a^{-/-}$ mice compared with the healthy FVB mice.

Pathways linked to the activation of Rxr were also significant in the pathway analysis. This receptor is the heterodimeric partner that mediates the effects of several nuclear hormone receptors such as Pxr, CAR, vitamin D receptor and Ppara, and regulates the expression of a large number of genes including those involved in xenobiotic metabolism[27]. Rxr homo- or heterodimers have been also suggested to modulate the immune response and T helper cell differentiation[28,29]. These results suggest that curcumin's effect on the xenobiotic metabolism and immune response could be regulated through those receptors in the colon of $mdr1a^{-/-}$ mice.

Rxr was not differentially expressed in the colon of curcumin-fed mice in the present study. However, this finding does not invalidate the hypothesis that dietary curcumin influences colon inflammation through those receptors. Indeed, previous study showed no marked change in the mRNA transcription levels of Rxr and suggests a post-translational regulation of the Rxr mRNA levels in the acute-phase response in hamster liver[30].

The transcriptional regulator Pxr was up-regulated (1·38-fold change) in the colon tissue of mice fed the curcumin diet. This supports the results of Kluth et al.[31], which showed that curcumin increases PXR gene expression in human liver carcinoma cells. The constitutive androstane receptor (CAR or Nr1i3) gene was not differentially expressed here. This supports results obtained by Langmann et al.[4], who showed no evidence of an altered CAR gene expression but a reduced amount of Pxr transcripts in colonic tissues from IBD patients. Beigneux et al.[32] suggest that CAR and Pxr response elements are quite similar and these two nuclear hormone receptors can compensate for each other's effects on their target genes. This may explain why the CAR/Rxr activation pathway was significantly affected by curcumin, but the CAR gene was not.

The Ppara gene was up-regulated (1·74-fold change) in the colon of mice fed dietary curcumin compared with mice fed

Table 7. Genes involved in fibrogenesis differentially expressed in the colon of multidrug resistance gene-deficient ($mdr1a^{-/-}$) mice fed the curcumin diet compared with the colon of mice fed the control diet*

Gene symbol	Description	Accession number	Mean fold change	q value†
Ccl5	Chemokine (C-C motif) ligand 5	BC033508	−3·45	<0·001
Cd14	CD14 molecule	NM_009841	−1·96	0·03
Col1a1	Collagen, type I, α 1	NM_007742	−3·23	0·001
Col1a2	Collagen, type I, α 2	NM_007743	−2·44	0·006
Col3a1	Collagen, type III, α 1 (Ehlers−Danlos syndrome type IV, autosomal dominant)	NM_009930	−2·22	0·04
Col4a1	Collagen, type IV, α 1	NM_009931	−1·96	0·005
Col4a2	Collagen, type IV, α 2	NM_009932	−1·85	0·02
Col5a1	Collagen, type V, α 1	NM_015734	−1·82	0·008
Cxcl2	Chemokine (C-X-C motif) ligand 2	NM_008176	−3·23	0·001
Fbn1	Fibrillin 1	NM_007993	−1·79	0·01
Icam1	Intercellular adhesion molecule 1 (CD54)	BC008626	−3·13	<0·001
Ifng	Interferon, γ	NM_008337	−2·78	0·008
Igf1	Insulin-like growth factor 1 (somatomedin C)	NM_010512	−2·38	<0·001
Igfbp5	Insulin-like growth factor binding protein 5	NM_010518	−3·33	0·001
Igfbp7	Insulin-like growth factor binding protein 7	NM_008048	−1·75	0·003
Il1b	IL 1, β	NM_008361	−5·00	0·003
Ltbp2	Latent transforming growth factor β binding protein 2	NM_013589	−2·63	<0·001
Mmp13	Matrix metallopeptidase 13 (collagenase 3)	NM_008607	−2·50	<0·001
Mmp14	Matrix metallopeptidase 14 (membrane-inserted)	NM_008608	−2·78	<0·001
Pdgfa	Platelet-derived growth factor α polypeptide	NM_008808	1·64	0·001
Sparc	Secreted protein, acidic, cysteine-rich (osteonectin)	NM_009242	−2·27	0·02
Tgfbr1	Transforming growth factor, β receptor I (activin A receptor type II-like kinase, 53 kDa)	NM_009370	−1·54	0·04
Tgfbr2	Transforming growth factor, β receptor II (70/80 kDa)	NM_009371	−1·85	<0·001
Timp1	TIMP metallopeptidase inhibitor 1	NM_011593	−1·96	0·001
Tnf	Tumour necrosis factor (TNF superfamily, member 2)	NM_013693	−1·70	0·01

* Genes were grouped in one or both of the following Ingenuity Pathways Analysis pathways: hepatic fibrosis and hepatic stellate cell activation.
† Only genes with a false discovery rate <5 % (q < 0·05) and fold change >1·5 were considered for pathway analysis.

the control diet. This suggests that Ppara could have an important modulatory role in colonic inflammation. Bunger *et al.* [33] have reported Ppara as an important transcriptional regulator involved in regulation of the immune system in the small intestine. Waxman [27], reviewing the role of CAR, Pxr and Ppara receptors, suggests that they modulate genes involved in xenobiotic metabolism in response to dietary or hormonal stimuli in the liver. In the present study, pathways linked to those receptors were significantly affected by curcumin, suggesting that the observed regulation of the xenobiotic and immune response in the colon of mice fed dietary curcumin might be related to the up-regulation of Pxr and Ppara and activation of Rxr.

Two pathways involved in fibrosis development (hepatic fibrosis and hepatic stellate cell activation) were down-regulated by dietary curcumin. No signs of fibrosis were observed in the histological analysis of colons in the present study, but a series of genes involved in these pathways were down-regulated, suggesting that curcumin could reduce fibrogenesis in the colon. Burke *et al.* [34] reviewed fibrogenesis in Crohn's disease and reported studies in which insulin-like growth factor 1, tissue inhibitor of metalloproteinase 1, collagen type III and transforming growth factor β receptors genes were up-regulated in fibroblasts and myofibroblasts in stricture of Crohn's disease patients. These and other genes involved in fibrosis development were down-regulated in the colon tissue of mice fed dietary curcumin compared with those fed the control diet (Table 7), suggesting that curcumin could indeed affect this process.

This genome-wide gene expression analysis of the colon from $mdr1a^{-/-}$ mice shows that dietary curcumin affects the expression of genes involved in several pathways of the xenobiotic metabolism, immune and inflammatory responses and fibrosis development. These results support Jagetia & Aggarwal [35], who suggest that curcumin is a pluripotent pharmacological agent acting through multiple molecular pathways. The global gene expression analyses have limitations, as some key points in the pathways can be regulated at the protein level. However, it does allow an unbiased overview of pathways affected by curcumin, showing the importance of this kind of study to understand and identify nutrient and gene interactions.

In the present study, dietary rutin did not reduce HIS in the colon of the $mdr1a^{-/-}$ mice; this could suggest that the lack of effect was due to the low dose used (0·1 % of rutin in the diet) comparing with results reported by Kim *et al.* [13], in which oral administration of 10 mg/kg had an anti-inflammatory effect in rats with trinitrobenzene sulfonic acid-induced colitis. However, Kwon *et al.* [14] used 0·01 and 0·1 % of rutin in the diet and also reported an improvement of inflammation in mice with chemically induced colitis. Rutin is a glycoside form of quercetin that is deglycosylated by microbial glycosidases, liberating quercetin in the colon. Kim *et al.* [13] suggest that quercetin is the active component of the rutin-mediated amelioration of inflammation in rats with chemically induced colitis. Ofer *et al.* [36], reviewing the effect of quercetin and others polyphenols on the transport of xenobiotics, showed that quercetin can interfere with the secretory transport process by interacting with P-glycoprotein (Abcb1 transporters). This mechanism could explain why 0·1 % of rutin (glycoside quercetin) in the diet reduced intestinal inflammation in the chemically induced colitis animal

Table 8. Genes linked to amino acid and fatty acid metabolisms differentially expressed in the colon of multidrug resistance gene-deficient ($mdr1a^{-/-}$) mice fed the curcumin diet compared with the colon of mice fed the control diet*

Gene symbol	Description	Accession number	Mean fold change	q value†
Abat	4-Aminobutyrate aminotransferase	NM_172961	3·25	0·001
Abp1	Amiloride binding protein 1 (amine oxidase)	NM_029638	3·40	0·001
Acaa2	Acetyl-coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-coenzyme A thiolase)	NM_177470	2·20	<0·001
Acad11	Acyl-coenzyme A dehydrogenase family, member 11	NM_175324	2·07	<0·001
Acadm	Acyl-coenzyme A dehydrogenase, C-4 to C-12 straight chain	NM_007382	1·59	0·003
Acox1	Acyl-coenzyme A oxidase 1, palmitoyl	NM_015729	2·12	0·001
Acsl3	Acyl-CoA synthetase long-chain family member 3	NM_028817	2·30	0·003
Acsl4	Acyl-CoA synthetase long-chain family member 4	NM_207625	−2·22	<0·001
Aldh1a1	Aldehyde dehydrogenase 1 family, member A1	NM_013467	1·58	0·04
Aldh1a7	Aldehyde dehydrogenase 1 family, subfamily A7	NM_011921	1·79	0·02
Aldh1b1	Aldehyde dehydrogenase 1 family, member B1	NM_028270	1·62	0·03
Adh1c	Alcohol dehydrogenase 1C (class I), γ polypeptide	NM_007409	1·98	0·003
Aldh2	Aldehyde dehydrogenase 2 family (mitochondrial)	NM_009656	2·02	0·006
Aldh3b1	Aldehyde dehydrogenase 3 family, member B1	NM_026316	−1·79	<0·001
Bcat1	Branched-chain aminotransferase 1	NM_001024468	−1·70	0·02
Ccbl1	Cysteine conjugate-β lyase; cytoplasmic (glutamine transaminase K, kyneurenine aminotransferase)	NM_172404	2·96	0·003
Cyp2c18	Cytochrome P450, family 2, subfamily C, polypeptide 18	NM_028089	3·52	0·002
Cyp2c19	Cytochrome P450, family 2, subfamily C, polypeptide 19	NM_010003	2·45	0·001
Cyp2c40	Cytochrome P450, family 2, subfamily C, polypeptide 40	NM_010004	5·07	<0·001
Cyp2c9	Cytochrome P450, family 2, subfamily C, polypeptide 9	NM_007815	2·54	0·002
Cyp2d10	Cytochrome P450, family 2, subfamily D, polypeptide 10	NM_010005	2·48	<0·001
Cyp2d13	Cytochrome P450, family 2, subfamily D, polypeptide 13	NM_133695	1·86	<0·001
Cyp2d26	Cytochrome P450, family 2, subfamily D, polypeptide 26	NM_029562	1·73	0·03
Cyp2d9	Cytochrome P450, family 2, subfamily D, polypeptide 9	NM_010006	2·98	<0·001
Cyp2f1	Cytochrome P450, family 2, subfamily F, polypeptide 1	NM_007817	1·91	0·009
Cyp2s1	Cytochrome P450, family 2, subfamily S, polypeptide 1	NM_028775	2·80	<0·001
Cyp3a5	Cytochrome P450, family 3, subfamily A, polypeptide 5	NM_007819	3·43	<0·001
Cyp3a7	Cytochrome P450, family 3, subfamily A, polypeptide 7	NM_007819	3·43	<0·001
Cyp7b1	Cytochrome P450, family 7, subfamily B, polypeptide 1	NM_007825	−1·67	0·002
Ddc	Dopa decarboxylase (aromatic L-amino acid decarboxylase)	NM_016672	1·65	0·01
Dpyd	Dihydropyrimidine dehydrogenase	NM_170778	1·60	0·03
Ech1	Enoyl coenzyme A hydratase 1, peroxisomal	NM_016772	2·10	<0·001
Gnmt	Glycine N-methyltransferase	NM_010321	−1·54	0·01
Hadh	Hydroxyacyl-coenzyme A dehydrogenase	AK199677	1·70	0·001
Hadhb	Hydroxyacyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A hydratase, β subunit	NM_145558	1·58	0·001
Hal	Histidine ammonia-lyase	NM_010401	−1·96	0·02
Hdc	Histidine decarboxylase	NM_008230	−2·86	0·007
Hmgcs1	3-Hydroxy-3-methylglutaryl-coenzyme A synthase 1	NM_145942	1·76	0·036
Indo	Indoleamine-pyrrole 2,3 dioxygenase	NM_008324	−4·76	0·004
Lpo	Lactoperoxidase	NM_080420	1·70	0·02
Maoa	Monoamine oxidase A	NM_173740	1·75	<0·001
Maob	Monoamine oxidase B	NM_172778	3·08	<0·001
Mpo	Myeloperoxidase	NM_010824	−1·75	0·04
Myo5b	Myosin VB	AK033484	1·71	0·03
Pla2g10	Phospholipase A2, group X	NM_011987	1·68	<0·001
Pla2g2d	Phospholipase A2, group IID	NM_011109	−1·72	0·04
Prdx6	Peroxiredoxin 6	NM_007453	2·12	0·02
Prdx6-rs1	Peroxiredoxin 6, related sequence 1	NM_177256	1·63	0·02
Sms	Spermine synthase	NM_009214	−1·52	0·02

* Genes were grouped in one or more of the following Ingenuity Pathways Analysis pathways: β-alanine metabolism; valine, leucine and isoleucine degradation; histidine metabolism; tryptophan metabolism, phenylalanine metabolism, fatty acid metabolism, linoleic acid metabolism.
† Only genes with a false discovery rate <5 % ($q < 0.05$) and fold change >1·5 were considered for pathway analysis.

model[14], but did not attenuate signs of colitis in $mdr1a^{-/-}$ mice. These mice are deficient in Abcb1 transporters and, therefore, quercetin (from rutin) could not interfere with secretory transport of xenobiotics and toxins.

Conclusions

The present study showed that curcumin, but not rutin, reduced signs of colonic inflammation in $mdr1a^{-/-}$ mice. The genome-wide microarray and pathway analyses allowed an unbiased overview of pathways affected by curcumin, showing the importance of this kind of study in understanding and identifying nutrient and gene interactions. The results suggest that curcumin acts through multiple molecular pathways to ameliorate inflammation. Curcumin might alleviate colonic inflammation via an up-regulation of xenobiotic metabolism and a down-regulation of immune response pathways mediated by Pxr and Ppara activation of Rxr. Curcumin also down-regulates genes involved in oxidative stress and fibrogenesis pathways. However, further studies are needed to elucidate the

mechanisms involved in the cross-talk between the pathways identified here. These results show the potential of genome-wide microarray and pathway analyses to study the effect of dietary supplements or functional foods that could prevent or reduce colonic inflammation.

References

1. Noble C, Nimmo E, Gaya D, Russell RK & Satsangi J (2006) Novel susceptibility genes in inflammatory bowel disease. *World J Gastroenterol* **12**, 1991–1999.
2. Goh J & O'Morain CA (2003) Review Article: nutrition and adult inflammatory bowel disease. *Aliment Pharmacol Ther* **17**, 307–320.
3. Sartor RB (2006) Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol* **3**, 390–407.
4. Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W & Schmitz G (2004) Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. *Gastroenterology* **127**, 26–40.
5. Panwala CM, Jones JC & Viney JL (1998) A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, *mdr1a*, spontaneously develop colitis. *J Immunol* **161**, 5733–5744.
6. Maggio-Price L, Shows D, Waggie K, Burich A, Zeng W, Escobar S, Morrissey P & Viney JL (2002) *Helicobacter bilis* infection accelerates and *H. hepaticus* infection delays the development of colitis in multiple drug resistance-deficient (*mdr1a − / −*) mice. *Am J Pathol* **160**, 739–751.
7. Middleton E Jr (1998) Effect of plant flavonoids on immune and inflammatory cell function. *Adv Exp Med Biol* **439**, 175–182.
8. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA & Sartor RB (1999) Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κ B kinase activity. *J Immunol* **163**, 3474–3483.
9. Salh B, Assi K, Templeman V, Parhar K, Owen D, Gomez-Munoz A & Jacobson K (2003) Curcumin attenuates DNB-induced murine colitis. *Am J Physiol Gastrointest Liver Physiol* **285**, G235–G243.
10. Sivalingam N, Hanumantharaya R, Faith M, Basivireddy J, Balasubramanian KA & Jacob M (2007) Curcumin reduces indomethacin-induced damage in the rat small intestine. *J Appl Toxicol* **27**, 551–560.
11. Sharma RA, Gescher AJ & Steward WP (2005) Curcumin: the story so far. *Eur J Cancer* **41**, 1955–1968.
12. Kampkotter A, Nkwonkam CG, Zurawski RF, Timpel C, Chovolou Y, Watjen W & Kahl R (2007) Investigations of protective effects of flavonoids quercetin and rutin on stress resistance in the model organism *Caenorhabditis elegans*. *Toxicology* **234**, 113–123.
13. Kim H, Kong H, Choi B, Yang Y, Kim Y, Lim MJ, Neckers L & Jung Y (2005) Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. *Pharm Res* **22**, 1499–1509.
14. Kwon KH, Murakami A, Tanaka T & Ohigashi H (2005) Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. *Biochem Pharmacol* **69**, 395–406.
15. Cruz T, Galvez J, Ocete MA, Crespo ME, Sanchez de Medina L-HF & Zarzuelo A (1998) Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. *Life Sci* **62**, 687–695.
16. Dommels YEM, Butts C, Zhu ST, Davy M, Martell S, Hedderly D, Barnett MPG, McNabb WC & Roy NC (2007) Characterization of intestinal inflammation and identification of related gene expression changes in *mdr1a*$^{-/-}$ mice. *Gene Nutr* **2**, 209–223.
17. Rozen S & Skaletsky HJ (2000) Primer3 on the WWW for general users and for biologist programmers. In *Bioinformatics Methods and Protocols: Methods in Molecular Biology*, pp. 365–386 [S Krawetz and S Misener, editors]. Totowa, NJ: Humana Press.
18. Ramakers C, Ruijter JM, Deprez RH & Moorman AF (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. *Neurosci Lett* **339**, 62–66.
19. Smyth GK (2005) Limma: linear models for microarray data. In *Bioinformatics and Computational Biology Solutions using R and Bioconductor*, pp. 397–420 [R Gentleman, V Carey, S Dudoit, R Irizarry and W Huber, editors]. New York: Springer.
20. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol* **3**, 1, article 3. http://www.bepress.com/sagmb/vol3/iss1/art3
21. Benjamini Y & Hochberg Y (1995) Controlling the false discovery rate – a practical and powerful approach to multiple testing. *J R Stat Soc B* **57**, 289–300.
22. Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, Bresnihan B & Fitzgerald O (2000) Serum amyloid A in the assessment of early inflammatory arthritis. *J Rheumatol* **27**, 58–63.
23. Ozseker F, Buyukozturk S, Depboylu B, Yilmazbayhan D, Karayigit E, Gelincik A, Genc S, Colakoglu B, Dal M & Issever H (2006) Serum amyloid A (SAA) in induced sputum of asthmatics: a new look to an old marker. *Int Immunopharmacol* **6**, 1569–1576.
24. Costello CM, Mah N, Häsler R, *et al.* (2005) Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. *PLoS Med* **2**, e199.

25. Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG & Muriel P (2007) Curcumin protects against acute liver damage in the rat by inhibiting NF-κB, proinflammatory cytokines production and oxidative stress. *Biochim Biophys Acta* **1770**, 989–996.

26. Camacho-Barquero L, Villegas I, Sánchez-Calvo JM, Talero E, Sánchez-Fidalgo S, Motilva V & Alarcón de la Lastra C (2007) Curcumin, a *Curcuma longa* constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. *Int Immunopharmacol* **7**, 333–342.

27. Waxman DJ (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. *Arch Biochem Biophys* **369**, 11–23.

28. Spilianakis CG, Lee GR & Flavell RA (2005) Twisting the Th1/Th2 immune response via the retinoid X receptor: lessons from a genetic approach. *Eur J Immunol* **35**, 3400–3404.

29. Stephensen CB, Borowsky AD & Lloyd KC (2007) Disruption of *Rxra* gene in thymocytes and T lymphocytes modestly alters lymphocyte frequencies, proliferation, survival and T helper type 1/type 2 balance. *Immunology* **121**, 484–498.

30. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C & Feingold KR (2000) The acute phase response is associated with retinoid X receptor repression in rodent liver. *J Biol Chem* **275**, 16390–16399.

31. Kluth D, Banning A, Paur I, Blomhoff R & Brigelius-Flohe R (2007) Modulation of pregnane X receptor- and electrophile responsive element-mediated gene expression by dietary polyphenolic compounds. *Free Radic Biol Med* **42**, 315–325.

32. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C & Feingold KR (2002) Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. *Biochem Biophys Res Commun* **293**, 145–149.

33. Bunger M, van den Bosch HM, van der Meijde J, Kersten S, Hooiveld GJ & Muller M (2007) Genome-wide analysis of PPARα activation in murine small intestine. *Physiol Genomics* **30**, 192–204.

34. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW & O'Connell PR (2007) Fibrogenesis in Crohn's disease. *Am J Gastroenterol* **102**, 439–448.

35. Jagetia GC & Aggarwal BB (2007) "Spicing up" of the immune system by curcumin. *J Clin Immunol* **27**, 19–35.

36. Ofer M, Wolffram S, Koggel A, Spahn-Langguth H & Langguth P (2005) Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? *Eur J Pharm Sci* **25**, 263–271.